Aesica has established a new high-capacity manufacturing facility following a $45 million investment at its Queenborough, Kent site. The 10,000-sq.-m. expansion has been constructed for the production of a solid dose medication used in treating one of the world’s most common lifestyle diseases: Type 2 diabetes in adults. The facility contains a large amount of highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system. ...